---
document_datetime: 2025-01-06 10:44:12
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zokinvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zokinvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.002741
conversion_datetime: 2025-12-18 21:08:52.514695
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zokinvy

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|----------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| T/0011               | Transfer of Marketing Authorisation                      | 26/09/2024                          | 21/10/2024                                  | SmPC, Labelling and PL           |                                   |
| PSUSA/11005 /202311  | Periodic Safety Update EU Single assessment - lonafarnib | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| S/0008              | 1st annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 25/01/2024   | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Zokinvy should be maintained.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11005 /202305 | Periodic Safety Update EU Single assessment - lonafarnib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 11/01/2024   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| II/0004             | Update of sections 4.2, 4.4, 4.5 and 6.6 of the SmPC in order to include updated drug-drug interaction information based on the final results from Drug- Drug Interaction study EIG-LNF-021. This is a Phase I, open-label, single-centre, two period, single sequence study evaluating the effect of autoinhibition, and the effects of fluconazole, a non- specific strong CYP2C9 inhibitor and moderate inhibitor of CYP2C9 and CYP3A, on the multiple-dose pharmacokinetics of lonafarnib. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 14/09/2023   | 19/10/2023 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                      |
| PSUSA/11005 /202211 | Periodic Safety Update EU Single assessment - lonafarnib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/06/2023   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                  |
| IB/0005/G           | This was an application for a group of variations. B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/04/2023   | n/a        |             |                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                       |            |            |                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| IAIN/0003 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 23/03/2023 | 19/10/2023 | Annex II and PL |
| IB/0001   | B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supportive data                                                                                                            | 07/02/2023 | n/a        |                 |